Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors

Inclusion Criteria: * Males or females aged 18 - 75 years (inclusive). * Histologically confirmed unresectable, recurrent or metastatic solid tumors. * At least one target lesion per the RECIST v1.1. * ECOG performance status of 0-1. * Minimum life expectancy \> 12 weeks. * Males or Females should be using adequate contraceptive measures throughout the study. * Females must not be pregnant at screening or have evidence of non-childbearing potential. * Signed Informed Consent Form. Exclusion Criteria: * Received or are receiving the following treatments: 1. Any anticancer therapy targeting MET, including TKIs, antibodies or antibody-drug conjugates. 2. Monoclonalor bispecific antibodies targeting EGFR. 3. Systemic anti-cancer treatment (Cytotoxicities and anti-cancer Traditional Chinese medicine or TKIs) within 2 weeks prior to the first dose of HS-20117. 4. Investigational anti-cancer drugs or antibodies or ADCs within 4 weeks prior to the first dose of HS-20117. 5. Local radiotherapy within 2 weeks prior to the first dose of HS-20117, more than 30% of bone marrow irradiation or large-area radiotherapy within 4 weeks before the first dose of HS-20117. 6. Presence of pleural effusion/ascites requiring clinical intervention; presence of pericardial effusion. 7. Major surgery within 4 weeks prior to the first dose of HS-20117. * Presence of Grade ≥ 2 toxicities due to prior anti-tumor therapy. * Presence of uncured secondary primary malignancies. * Untreated, or active central nervous system metastases. * Severe, uncontrolled or active cardiovascular disorders. * Serious infection within 4 weeks prior to the first dose of HS-20117.